NYSE:QGEN - Qiagen Stock Price, Forecast & News

Qiagen trades on the New York Stock Exchange (NYSE) under the ticker symbol "QGEN."

Qiagen NV (NYSE:QGEN) announced its quarterly earnings data on Wednesday, October, 30th. The company reported $0.36 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.35 by $0.01. The business earned $382.70 million during the quarter, compared to the consensus estimate of $382.98 million. Qiagen had a negative net margin of 1.68% and a positive return on equity of 12.24%. The firm's quarterly revenue was up 1.3% compared to the same quarter last year. During the same quarter last year, the firm earned $0.35 earnings per share. View Qiagen's Earnings History.

Qiagen is scheduled to release their next quarterly earnings announcement on Monday, February 3rd 2020. View Earnings Estimates for Qiagen.

Qiagen issued an update on its FY19 earnings guidance on Wednesday, October, 30th. The company provided EPS guidance of $1.43-1.44 for the period, compared to the Thomson Reuters consensus estimate of $1.38. The company issued revenue guidance of ~$1.56 billion, compared to the consensus revenue estimate of $1.53 billion.

17 brokerages have issued 12 month price targets for Qiagen's stock. Their forecasts range from $31.00 to $48.00. On average, they expect Qiagen's stock price to reach $37.38 in the next year. This suggests that the stock has a possible downside of 10.0%. View Analyst Price Targets for Qiagen.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Qiagen in the last year. There are currently 8 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Qiagen.

Media headlines about QGEN stock have trended negative recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Qiagen earned a news sentiment score of -3.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Qiagen.

Qiagen saw a increase in short interest in October. As of October 15th, there was short interest totalling 4,010,000 shares, an increase of 13.3% from the September 15th total of 3,540,000 shares. Based on an average daily volume of 1,390,000 shares, the short-interest ratio is currently 2.9 days. Currently, 1.9% of the shares of the company are sold short. View Qiagen's Current Options Chain.

Some companies that are related to Qiagen include Seattle Genetics (SGEN), NOVOZYMES A/S/S (NVZMY), Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), BioNTech (BNTX), Moderna (MRNA), argenx (ARGX), Repligen (RGEN), China Biologic Products (CBPO), Spark Therapeutics (ONCE), bluebird bio (BLUE), Adaptive Biotechnologies (ADPT), Ablynx (ABLYF), Allogene Therapeutics (ALLO) and Crispr Therapeutics (CRSP).

Based on aggregate information from My MarketBeat watchlists, some companies that other Qiagen investors own include Netflix (NFLX), Gilead Sciences (GILD), NVIDIA (NVDA), Boeing (BA), Twitter (TWTR), Cisco Systems (CSCO), QUALCOMM (QCOM), Activision Blizzard (ATVI), Exelixis (EXEL) and Starbucks (SBUX).

Qiagen's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Massachusetts Financial Services Co. MA (5.55%), Hardman Johnston Global Advisors LLC (1.77%), State Street Corp (0.96%), First Trust Advisors LP (0.68%), Sycomore Asset Management (0.63%) and Parametric Portfolio Associates LLC (0.43%).

QGEN stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Assenagon Asset Management S.A., Hardman Johnston Global Advisors LLC, Parametric Portfolio Associates LLC, Man Group plc, Exane Asset Management, Zurcher Kantonalbank Zurich Cantonalbank and Squarepoint Ops LLC.

QGEN stock was purchased by a variety of institutional investors in the last quarter, including Sycomore Asset Management, Massachusetts Financial Services Co. MA, Phoenix Holdings Ltd., Point72 Asset Management L.P., Fisher Asset Management LLC, SG Americas Securities LLC, Sector Gamma AS and Russell Investments Group Ltd..

Shares of QGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of QGEN stock can currently be purchased for approximately $41.55.

Qiagen has a market capitalization of $9.37 billion and generates $1.50 billion in revenue each year. The company earns $190.38 million in net income (profit) each year or $1.34 on an earnings per share basis. Qiagen employs 4,952 workers across the globe.View Additional Information About Qiagen.

The official website for Qiagen is http://www.qiagen.com/.

Qiagen's mailing address is HULSTERWEG 82, VENLO P7, 5912 PL. The company can be reached via phone at 31-77-355-6600 or via email at [email protected]